Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review.
Simple Summary: The combination of docetaxel and ramucirumab is a standard second-line treatment for patients with advanced metastatic non-small-cell lung cancer (NSCLC); however, evidence supporting this regimen comes from the REVEL trial conducted before the introduction of immune checkpoint inhib...
| Publicado en: | Current Oncology Vol. 32; no. 11; pp. 612 - 628 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |